Professor Luo Junhang from the First Affiliated School of CUHK visited Shenzhen Cell Valley
Accompanied by Sun Rui, director of the Marketing Department, the team visited the Smart exhibition Hall, and had a preliminary understanding of the company's strategic development layout, corporate development history and status quo of cell therapy, service platform construction and corporate vision, and had a deeper understanding of the all-round one-stop service process provided by Shenzhen Cell Valley from basic scientific research to clinical application transformation.
At the symposium, Minister Sun Rui introduced in detail the current situation of cell therapy at home and abroad, the strategic layout of our company and the core technology. Professor Wang said that cell therapy has made remarkable achievements in improving patient survival and reducing the burden of cancer. Using the domestic leading retroviral vector GMP industrial production process, our company has provided high-quality and safe customized target CAR cell preparation services for many well-known medical institutions at home and abroad. Dozens of patients with recurrent or drug-resistant blood tumors who did not respond to previous treatment experienced significant remission after treatment with CAR T cells prepared by the Cell Valley team. At the same time, the NK and CAR-NK cell therapy products recently launched by Cell Valley have been widely used in clinical studies of solid tumors such as liver cancer and pancreatic cancer and autoimmune diseases. Shenzhen Cell Valley has always adhered to the mission values of "cells benefit all beings and genes create the future", and is committed to solving the key constraints such as technology, cost, production capacity and talent in cell therapy drugs/clinical treatment, and opening up more treatment ways for patients.
Professor Luo Junhang of the First Affiliated Hospital of Sun Yat-sen University said that cell therapy is becoming a new focus of the development of the medical and health industry, and the future cell clinical treatment model will be full cycle and all-round, and its popularization and promotion cannot be achieved without the unremitting technological development of the scientific research team and the application and transformation of the high-level clinical treatment team.
Both parties said that they will give full play to their respective technical resources, core teams and platform advantages, and jointly promote the contribution of cell therapy in the scientific research and clinical application of urology related tumors.
